StockData
Galectin Therapeutics Inc logo

Galectin Therapeutics Inc (GALT) stock

GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.98+0.07 (+2.41%)

Close on Nov 18, 2026Market cap $300.53MP/E –Yield –

Galectin Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Galectin Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$15.62M. For fiscal 2025 it was -$20.09M. The highest annual figure on record is -$4.88M in fiscal 2010.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$20.09M–
FY2024Dec 31, 2024-$42.43M–
FY2023Dec 31, 2023-$38.07M–
FY2022Dec 31, 2022-$38.35M–
FY2021Dec 31, 2021-$30.18M–
FY2020Dec 31, 2020-$23.44M–
FY2019Dec 31, 2019-$13.44M–
FY2018Dec 31, 2018-$13.60M–
FY2017Dec 31, 2017-$16.25M–
FY2016Dec 31, 2016-$21.48M–
FY2015Dec 31, 2015-$20.08M–
FY2014Dec 31, 2014-$15.43M–
FY2013Dec 31, 2013-$12.10M–
FY2012Dec 31, 2012-$9.90M–
FY2011Dec 31, 2011-$10.41M–
FY2010Dec 31, 2010-$4.88M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.98M–
Q1 FY2026Mar 31, 2026-$4.08M–
Q4 FY2025Dec 31, 2025-$3.37M–
Q3 FY2025Sep 30, 2025-$4.20M–
Q2 FY2025Jun 30, 2025-$4.63M–
Q1 FY2025Mar 31, 2025-$7.90M–
Q4 FY2024Dec 31, 2024-$12.43M–
Q3 FY2024Sep 30, 2024-$9.07M–
Q2 FY2024Jun 30, 2024-$11.29M–
Q1 FY2024Mar 31, 2024-$9.65M–
Q4 FY2023Dec 31, 2023-$9.56M–
Q3 FY2023Sep 30, 2023-$9.17M–
Q2 FY2023Jun 30, 2023-$9.00M–
Q1 FY2023Mar 31, 2023-$10.34M–
Q4 FY2022Dec 31, 2022-$10.63M–
Q3 FY2022Sep 30, 2022-$8.12M–
Q2 FY2022Jun 30, 2022-$9.66M–
Q1 FY2022Mar 31, 2022-$9.94M–
Q4 FY2021Dec 31, 2021-$7.43M–
Q3 FY2021Sep 30, 2021-$8.24M–
Q2 FY2021Jun 30, 2021-$8.19M–
Q1 FY2021Mar 31, 2021-$6.32M–
Q4 FY2020Dec 31, 2020-$7.83M–
Q3 FY2020Sep 30, 2020-$5.93M–
Q2 FY2020Jun 30, 2020-$6.10M–
Q1 FY2020Mar 31, 2020-$3.58M–
Q4 FY2019Dec 31, 2019-$5.19M–
Q3 FY2019Sep 30, 2019-$2.86M–
Q2 FY2019Jun 30, 2019-$3.02M–
Q1 FY2019Mar 31, 2019-$2.37M–
Q4 FY2018Dec 31, 2018-$2.99M–
Q3 FY2018Sep 30, 2018-$2.68M–
Q2 FY2018Jun 30, 2018-$3.76M–
Q1 FY2018Mar 31, 2018-$4.18M–
Q4 FY2017Dec 31, 2017-$2.37M–
Q3 FY2017Sep 30, 2017-$4.41M–
Q2 FY2017Jun 30, 2017-$4.51M–
Q1 FY2017Mar 31, 2017-$4.95M–
Q4 FY2016Dec 31, 2016-$4.60M–
Q3 FY2016Sep 30, 2016-$4.54M–

More Galectin Therapeutics figures

See a number that looks wrong?